Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews


Print Page Follow BioNews on Twitter BioNews RSS feed

Like the Progress Educational Trust on Facebook






Gene therapy beneficial but not permanent in serious immune disorder

05 March 2012

By Ayesha Jadoon

Appeared in BioNews 647

Early trials in patients with chronic granulomatous disorder (x-CGD), a recessive X-linked condition that affects the immune system, have shown signs of success following the use of gene therapy. The observed boost in immunity of those undergoing treatment was only temporary, however, and the faulty gene causing x-CGD was not corrected permanently.

Five patients with x-CGD were treated by doctors at Great Ormond street Hospital (GOSH), London and UCL's Institute of Child Health. 'Gene therapy continues to make exciting progress. This is the third immune disease to respond to gene therapy in our programme', said Professor Adrian Thrasher, a senior member of the team. The response of the most recent patient treated with a new vector was 'very good', he said.

X-CGD is a rare inherited disorder that affects four in one million people. People affected by x-CGD have a faulty bone marrow gene which means the immune cells that fight off fungal and bacterial infections do not function correctly. This leaves patients exposed to infections, which can be potentially life-threatening and can lead to long periods in hospital.

The only cure for x-CGD is through bone marrow transplantation. Some patients are not able to undergo the procedure, however, and finding a matching donor can be difficult. For these patients, gene therapy may be the only option.

Using an inactive virus to act as a vector, the researchers inserted a working copy of the faulty gene into the patients' blood stem cells. The stem cells were then reintroduced into the body where they can produce the immune cells deficient in patients with x-CGD.

X-CGD is the third immune disease to have been treated with a positive outcome at GOSH following reported successes in treating X-linked severe combined immunodeficiency (x-SCID) and adenosine deaminase severe combined immune deficiency (ada-SCID).

Some of the patients involved in the trials for x-SCID and ada-SCID showed a permanent correction in their immune system. However, two patients, one based at GOSH and the other who took part in a trial at a sister facility in France, developed leukaemia. The researchers say they have developed new vectors in an attempt to reduce this risk.

Since most immune diseases have a similar underlying cause, Professor Adrian Thrasher is hoping that the success in the x-CGD trial may be indicate future breakthroughs for other immune disorders are not far away.

'We currently hope to treat patients with four different immune diseases at GOSH this year. We reported in August 2011 that […] patients with the first two diseases on our programme, x-SCID or ada-SCID showed clear clinical benefit. Trials for a fourth disease, Wiskott-Aldrich syndrome, have also recently started, while those for cancer, HIV (human immunodeficiency virus), and inherited skin disorders are close to clinical application', said Professor Thrasher.

Meanwhile, the new vector trial may provide hope to others affected by x-CGD. 'The CGD Society started funding gene therapy projects in 1994 and we are hugely excited by these developments', said Susan Walsh, head of research and specialist services at the charity, the CGD Research Trust. 'In 2005 we took a major strategic decision to allocate over £1m into developing a new and safer vector. It's wonderful to see this work come to fruition and know that gene therapy is being used to help very seriously ill patients with CGD'.

 

 

SOURCES & REFERENCES
BBC News | 29 February 2012
 
Guardian | 29 February 2012
 
Great Ormond Street Hospital for Children (press release) | 29 February 2012
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

15 July 2013 - by Nicola Davis 
A clinical trial of a gene therapy to treat children with two types of severe genetic disease has shown early signs of success... [Read More]
25 March 2013 - by John Brinsley 
Early results of an experimental gene therapy against an aggressive form of leukaemia have been hailed by researchers as showing 'life saving potential'.... [Read More]
17 December 2012 - by Joseph Jebelli 
A seven-year-old girl with a highly aggressive form of leukaemia may have been 'cured' by an experimental therapy that harnesses the body's immune system to seek out and destroy the disease.... [Read More]
03 December 2012 - by Daryl Ramai 
Scientists have discovered a gene that controls the immune response against infection... [Read More]

30 August 2011 - by Rosemary Paxman 
Over a dozen children with 'boy in bubble' syndrome are alive and well, with functioning immune systems, nine years after undergoing gene therapy to correct their disorder, researchers report.... [Read More]
02 February 2009 - by Dr Megan Allyse 
Researchers in Italy and Israel have announced that they have successfully used gene therapy to treat ten children who suffer from a rare form of severe combined immunodeficiency (SCID) called ADA-SCID. The trial marks one of the first successful uses of gene therapy since past trials of... [Read More]
03 April 2006 - by BioNews 
A team of scientists based in Frankfurt, Germany, has become the world's first to treat a rare and 'incurable' hereditary immune disease in adults, using gene therapy. Gene therapy has been used successfully in the past, but this has generally been in the treatment of children. Over the past two... [Read More]
13 March 2005 - by BioNews 
Doctors at Great Ormond Street Hospital (GOSH) for Children and the Institute of Child Health have successfully treated a second disease using pioneering gene therapy treatment. The four-year old boy who received the therapy was affected by ada-SCID, a life-threatening immune deficiency condition. He is now attending pre-school and living... [Read More]
01 October 2001 - by BioNews 
Great Ormond Street Hospital in London has a brand new laboratory which will be used for research into genetic diseases and especially gene therapy for sick children. The new unit is partly funded by the Jeans for Genes campaign (see Recommends for details) and the Institute for Child Health. The... [Read More]

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions

 


 

- click here to enquire about using this story.

Printer Friendly Page

Published by the Progress Educational Trust

FREE EVENT
GENOMIC MEDICINE NEEDS YOU


'Genomic Medicine Needs You - Do You Need Genomic Medicine?', a FREE public event being organised by the Progress Educational Trust in central Oxford on the evening of Thursday 16 October 2014

Oxford, 16 October
Click HERE for details

BREAST CANCER POLL

BREAST CANCER POLL - Have your say about breast cancer and genetic testing HERE

Have your say about breast cancer and genetic testing HERE

Good Fundraising Code

Become a Friend of PET HERE, and give the Progress Educational Trust a regular donation